Pertinax Pharma03.23.18
Pertinax Pharma has appointed Paul Williams as business development manager. The new position, which bolsters the company’s commercial team, forms an integral part of the business strategy to secure expansion primarily by growing revenues from the international woundcare sector.
“Paul’s appointment comes as we ramp up our presence in the global woundcare market, having already established preliminary discussions with a number of multinational providers. Our intention is to proliferate our Pertinax technology so that it is one of the first things our customers’ customers ask for when commissioning new products,” said Dr. Michele Barbour, CEO. "Mr. Williams, working alongside Pertinax Pharma’s Chairman Nigel Brooksby, will help to execute the commercial plan to develop and nurture the company’s client base. The intention is to focus on increasing sales from large and medium sized commercial entities.
Prior to joining Pertinax, Williams held senior account management and strategic sales roles at SCAPA Healthcare and BBI Solutions. He has emerged as a prominent figure in his industry through his established track record for winning new business in the global woundcare dressings market.
“We are delighted with Paul’s appointment. It’s a significant step for our ambitions. His extensive international network of industry contacts in the R&D, production, commercial and marketing fields, together with his expertise and experience, makes him a perfect fit for the role. Indeed, he will prove an invaluable asset to the company as we drive the business forward and implement our strategy for growth,” Barbour added.
The patented Pertinax technology has strong market potential in multiple sectors with the company forecasting rapid growth from sales to woundcare providers. Williams said, “What I am excited about is just how disruptive it will be. In my view, within a couple of years, you will see all major woundcare providers looking to adopt this type of innovation.”
Pertinax Pharma Ltd., originally a spinout from the University of Bristol in the United Kingdom, was established in April 2015 to commercialize its proprietary and patented Pertinax technology. The antimicrobial material has wide ranging potential application across the wound care, dentistry, medical device, veterinary, and broader markets. Pertinax provides controlled and sustained release of chlorhexidine (CHX), overcoming the short duration of antimicrobial activity of conventional CHX products. The antimicrobial can be formulated to persist for days, weeks, months or years depending on the application. Pertinax requires lower quantities of CHX, with continuous antimicrobial function provided by less frequent applications, and it also exhibits lower cytotoxicity than equivalent concentrations of conventional CHX.
“Paul’s appointment comes as we ramp up our presence in the global woundcare market, having already established preliminary discussions with a number of multinational providers. Our intention is to proliferate our Pertinax technology so that it is one of the first things our customers’ customers ask for when commissioning new products,” said Dr. Michele Barbour, CEO. "Mr. Williams, working alongside Pertinax Pharma’s Chairman Nigel Brooksby, will help to execute the commercial plan to develop and nurture the company’s client base. The intention is to focus on increasing sales from large and medium sized commercial entities.
Prior to joining Pertinax, Williams held senior account management and strategic sales roles at SCAPA Healthcare and BBI Solutions. He has emerged as a prominent figure in his industry through his established track record for winning new business in the global woundcare dressings market.
“We are delighted with Paul’s appointment. It’s a significant step for our ambitions. His extensive international network of industry contacts in the R&D, production, commercial and marketing fields, together with his expertise and experience, makes him a perfect fit for the role. Indeed, he will prove an invaluable asset to the company as we drive the business forward and implement our strategy for growth,” Barbour added.
The patented Pertinax technology has strong market potential in multiple sectors with the company forecasting rapid growth from sales to woundcare providers. Williams said, “What I am excited about is just how disruptive it will be. In my view, within a couple of years, you will see all major woundcare providers looking to adopt this type of innovation.”
Pertinax Pharma Ltd., originally a spinout from the University of Bristol in the United Kingdom, was established in April 2015 to commercialize its proprietary and patented Pertinax technology. The antimicrobial material has wide ranging potential application across the wound care, dentistry, medical device, veterinary, and broader markets. Pertinax provides controlled and sustained release of chlorhexidine (CHX), overcoming the short duration of antimicrobial activity of conventional CHX products. The antimicrobial can be formulated to persist for days, weeks, months or years depending on the application. Pertinax requires lower quantities of CHX, with continuous antimicrobial function provided by less frequent applications, and it also exhibits lower cytotoxicity than equivalent concentrations of conventional CHX.
